Flerie EBITDA TCAC 5A

Que fait Flerie ? Flerie AB, listed on the Stockholm Stock Exchange under the ticker FLERIE.ST, is a pharmaceutical company based in Solna, Sweden. The company has 6 employees and completed its initial public offering (IPO) on October 11, 2016. Flerie AB operates within the healthcare sector, specifically in the pharmaceuticals industry. The company's website is https://www.indexpharma.com/. Flerie AB is a parent company for InDex Pharmaceuticals AB and InDex Diagnostics AB. The company is engaged in the development of drugs for the treatment of diseases such as inflammation and cancer. It has a drug candidate named cobitolimod, which is intended for the treatment of ulcerative colitis. Additionally, Flerie AB develops a platform of patent-protected substances known as DNA-based ImmunoModulatory Sequences (DIMS), designed to treat various immunological diseases. The company also offers a diagnostic kit called DiBiCol, a PCR-based method that monitors seven biomarkers specific to ulcerative colitis or Crohn's disease from a single colonic biopsy. Shareholders of Flerie AB include SEB Venture Capital, Industrifonden, and NeoMed Management. The company's focus is on pharmaceutical development, with an emphasis on innovative treatments for inflammatory and immunological conditions. Flerie est l'une des entreprises les plus populaires sur Eulerpool.